Scientists hunt for immune weak spots in B-Cell cancers
NCT ID NCT07515313
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two immune-related proteins, CD274 and CD276, in people newly diagnosed with B-cell cancers like leukemia and lymphoma. Researchers will use a blood test to measure these proteins and see how they help cancer hide from the immune system. The goal is to find better ways to diagnose and treat these cancers in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE B LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- Double-Targeted immune cells take aim at Hard-to-Treat blood cancers
- Double-Pronged immune cells take aim at blood cancers
- Double-Pronged CAR-T cells take aim at Hard-to-Treat blood cancers
- Off-the-Shelf CAR t cells take on tough blood cancers
- Hidden danger: why some patients can't shake COVID-19